Future Perspectives in R/R MM

Panelist discusses the current acceleration of new therapies for multiple myeloma. In the future, oncologists will be able to use CAR T and bispecific therapies more efficiently, and they will also have new tools including new CAR T therapies and bispecifics that will require less manufacturing time, have fewer AEs, and be more effective regarding the targeted disease.

EP: 1.R/R MM: Treating Patients with CNS Metastases Involvement

EP: 2.Optimal Dosing Strategies and Managing AEs

EP: 3.R/R MM: Bispecifics in R/R MM: Key Takeaways

EP: 4.R/R MM: Insights Into Optimal Dosing for Bispecifics

EP: 5.Bispecifics in R/R MM: AE Management and Sequencing

Now Viewing

EP: 6.Future Perspectives in R/R MM

EP: 7.R/R MM Treatment Landscape: Role of Bispecifics

EP: 8.Clinical Pearls Surrounding the Use of Bispecifics in R/R MM

Video content above is prompted by the following

• Are there any therapies you wish to highlight that you are most excited about for the management of R/R MM?

Recent Videos